de Morais S M, Wells P G
Faculty of Pharmacy, University of Toronto, Canada.
J Pharmacol Exp Ther. 1988 Oct;247(1):323-31.
Over 60% of the analgesic/antipyretic drug acetaminophen is eliminated by glucuronidation, which competes with a toxifying pathway involving cytochromes P-450-catalyzed bioactivation to a hepatotoxic reactive intermediate. A genetic deficiency of bilirubin UDP-glucuronyl transferase (GT) occurs in 5 to 7% of the population (Gilbert's disease, Crigler-Najjar syndrome) and this could predispose such people to acetaminophen hepatotoxicity. This hypothesis was evaluated in the homozygous Gunn rat, which is similarly deficient in GT, and the heterozygous Gunn rat, which has intermediary GT activity. Acetaminophen, 1 g/kg, was administered by gavage to animals 6 and 11 weeks of age, and age-matched Wistar rats as controls. Hepatic and renal cellular damage were assessed by respective increases in the peak plasma concentration of alanine aminotransferase and the blood urea nitrogen concentration, and confirmed by histological examination. Acetaminophen and metabolites were measured by high-performance liquid chromatography. Compared to Wistar controls, Gunn rats demonstrated up to a 110-fold greater hepatotoxic response to acetaminophen, with significantly lower production of the glucuronide conjugate and higher plasma concentrations of acetaminophen. Elevated acetaminophen concentrations correlated positively with both increased production of the acetaminophen-cysteine conjugate, reflecting bioactivation and hepatotoxicity. Older Gunn but not Wistar rats showed up to 26-fold more hepatotoxicity compared to their younger counterparts. In younger animals, heterozygotes demonstrated intermediary hepatotoxicity between homozygotes and Wistar controls. Hepatotoxicity was similar in the older heterozygotic and homozygotic Gunn rats, as was renal toxicity, which was enhanced 2- to 3-fold over controls. These results indicate that a genetic deficiency in bilirubin GT can be an important determinant of acetaminophen bioactivation and toxicity.
超过60%的解热镇痛药对乙酰氨基酚是通过葡萄糖醛酸化作用消除的,这一过程与一条涉及细胞色素P-450催化生物活化形成肝毒性反应中间体的毒性代谢途径相互竞争。5%至7%的人群存在胆红素UDP-葡萄糖醛酸基转移酶(GT)基因缺陷(吉尔伯特氏病、克里格勒-纳贾尔综合征),这可能使这些人易患对乙酰氨基酚肝毒性。在同样缺乏GT的纯合子冈恩大鼠以及具有中等GT活性的杂合子冈恩大鼠中对这一假说进行了评估。将1 g/kg的对乙酰氨基酚经口灌胃给予6周龄和11周龄的动物以及年龄匹配的Wistar大鼠作为对照。通过丙氨酸转氨酶的血浆峰值浓度和血尿素氮浓度的相应升高来评估肝和肾细胞损伤,并通过组织学检查加以证实。采用高效液相色谱法测定对乙酰氨基酚及其代谢产物。与Wistar对照相比,冈恩大鼠对对乙酰氨基酚的肝毒性反应高达110倍,葡萄糖醛酸结合物的生成显著减少,对乙酰氨基酚的血浆浓度更高。对乙酰氨基酚浓度升高与对乙酰氨基酚-半胱氨酸结合物生成增加均呈正相关,反映了生物活化和肝毒性。与年轻的冈恩大鼠相比,老年冈恩大鼠(而非Wistar大鼠)的肝毒性高达26倍。在年轻动物中,杂合子的肝毒性介于纯合子和Wistar对照之间。老年杂合子和纯合子冈恩大鼠的肝毒性相似,肾毒性也相似,且肾毒性比对照增强了2至3倍。这些结果表明,胆红素GT基因缺陷可能是对乙酰氨基酚生物活化和毒性的一个重要决定因素。